Evaluating the effect of bowel preparation plus oral Rifaximin in Brachytherapy for endometrial and cervical Cancer

Phase 3

• Conditions: Condition 1: Endometrial cancer. Condition 2: Cervical cancer.; Malignant neoplasm of endometrium; Malignant neoplasm of cervix uteri, unspecified; C54.1; C53.9

• Registration Number: IRCT20200208046412N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

pathology based endometrial and cervical cancer
doing surgical treatment before brachytherapy
correct cylinder insertion

Exclusion Criteria

no surgery before brachyhterapy treatment
weight above 100 killogram causing not to do MRI

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rectal volume. Timepoint: Before(basement) and 7 days after oral Rifaximin. Method of measurement: HDR plus 3.0.8 brachytherapy , treatment planning, Bebig & Ziegler company.;Rectal Dose-volume parameters. Timepoint: Before(basement) and 7 days after oral Rifaximin. Method of measurement: HDR plus 3.0.8 brachytherapy treatment planning, Bebig & Ziegler company.